UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.9% · net new positions -4.8% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | n/a |
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 5.35M | +0.4% | $2.24B | 0.0% | ▲ Add | 2 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passive) | 4.42M | -0.7% | $1.85B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 2.17M | +2.6% | $911.11M | 1.2% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 1.92M | -11.3% | $805.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.40M | -3.1% | $586.38M | 0.1% | ▼ Trim | 6 | SEC ↗ ×7 |
| 6 | Geode Capital Management ✦ (passive) | 1.25M | +4.1% | $522.91M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 986.48K | -22.5% | $413.54M | 0.3% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | JPMorgan Chase ✦ | 495.87K | n/a | $207.88M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 9 | Morgan Stanley ✦ | 438.80K | n/a | $183.95M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | T. Rowe Price ✦ | 300.93K | +162.8% | $126.15M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 273.98K | +94.3% | $114.86M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 258.58K | +235.5% | $108.40M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 250.33K | -41.0% | $104.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 14 | Arrowstreet Capital ✦ | 208.53K | -38.5% | $87.42M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 99.78K | New | $41.83M | 0.1% | New | 1 | SEC ↗ |
| 16 | Goldman Sachs Group ✦ | 81.54K | n/a | $34.18M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | Gotham Asset Management ✦ | 80.96K | -9.4% | $33.94M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 64.71K | +199.5% | $27.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Fisher Asset Management ✦ | 23.58K | +26.8% | $9.89M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 16.09K | +82.8% | $6.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 16.07K | -91.8% | $6.73M | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $41.83M | 0.1% |
Exited
| Norges Bank | $136.45M | was 0.0% |
| Marshall Wace | $79.45M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 844 holders, 41.22M shares, $23.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 401 sh · $215,959
Officer, Director · 391 sh · $212,185
Officer, Director · 40 sh · $21,754
Officer, Director · 239 sh · $128,964
Officer, Director · 535 sh · $286,582
Officer, Director · 760 sh · $408,681
Officer, Director · 1.02K sh · $544,296
Officer, Director · 1.82K sh · $969,579
Officer, Director · 240 sh · $127,314
Officer, Director · 2.38K sh · $1.27M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology